pioglitazone

pioglitazone is an oral antidiabetic medication belonging to the thiazolidinedione class of drugs. It is primarily used in the management of type 2 diabetes mellitus as an adjunct to diet and exercise. The drug functions as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPARγ), a mechanism distinct from other classes like sulfonylureas or metformin. It is marketed globally under brand names including Actos by Takeda Pharmaceutical Company.

Medical uses

Pioglitazone is indicated for improving glycemic control in adults with type 2 diabetes mellitus, often in combination with other agents like metformin, a sulfonylurea, or insulin. Clinical studies, such as the PROactive trial, have demonstrated its efficacy in reducing HbA1c levels. It may also be used in certain cases of non-alcoholic steatohepatitis due to its effects on hepatic steatosis. The American Diabetes Association includes it in treatment guidelines, though its use is typically reserved after considering potential risks.

Adverse effects

Common adverse reactions include weight gain, edema, and an increased risk of heart failure. Significant concerns involve a potential elevated risk of bladder cancer, leading to regulatory reviews by the U.S. Food and Drug Administration and the European Medicines Agency. Other serious risks include fractures, particularly in postmenopausal women, and hepatotoxicity. The black box warning in the United States highlights the heart failure risk, necessitating careful patient selection and monitoring.

Pharmacology

Pioglitazone acts as a selective agonist for the peroxisome proliferator-activated receptor gamma (PPARγ) found primarily in adipose tissue, skeletal muscle, and the liver. Activation of this nuclear receptor modulates the transcription of genes involved in glucose and lipid metabolism, enhancing insulin sensitivity. It is metabolized primarily in the liver by enzymes of the CYP2C8 and CYP3A4 cytochrome P450 systems. The major active metabolite is M-IV (keto-derivative), which contributes to its prolonged pharmacodynamic effects.

History

Pioglitazone was discovered by researchers at Takeda Pharmaceutical Company in Japan and was first approved for medical use in the United States in 1999. Its development followed that of the first thiazolidinedione, troglitazone, which was withdrawn due to idiosyncratic liver injury. The drug gained widespread use but faced significant scrutiny after the Rosiglitazone controversy, leading to renewed safety studies. Key post-marketing studies like the PROactive trial and research by the Kaiser Permanente division of research informed its current risk profile.

Society and culture

Pioglitazone has been the subject of extensive litigation, particularly in the United States, over allegations linking it to bladder cancer. The drug was a major revenue source for Takeda Pharmaceutical Company, especially following the market withdrawal of rosiglitazone. Its cost and access are influenced by generic drug availability following patent expirations in key markets like the European Union and the United States. The medication is listed on the World Health Organization's List of Essential Medicines, underscoring its role in global diabetes care. Category:Antidiabetic drugs Category:Thiazolidinediones Category:Takeda Pharmaceutical Company